Lipoproteína: o fator de risco cardiovascular genético negligenciado e as terapias de silenciamento gênico após o resultado do LP Horizon

Lipoprotein is a lipid particle of predominantly genetic origin whose elevated plasma levels are causally and independently associated with the risk of atherosclerotic cardiovascular disease and calcific aortic stenosis. Despite its significant population prevalence an estimated 20% of individuals carry risk-associated concentrations Lp measurement remains absent from most routine cardiovascular screening strategies, constituting a neglected risk factor in clinical practice. This article reviews the pathophysiology of Lp, its genetic determination by the LPA locus, the epidemiological and genetic evidence supporting a causal relationship with cardiovascular outcomes, and the emerging therapeutic landscape. Traditionally, available pharmacological interventions such as statins exert minimal or no effect on Lp. However, the advent of gene-silencing therapies based on antisense oligonucleotides and small interfering RNA represents a paradigm shift. The phase 2 Lp(a)HORIZON trial demonstrated that olpasiran, an ASO targeting apo mRNA, produced dose dependent reductions of up to 80% in Lp levels in patients with established cardiovascular disease, with an acceptable safety profile (Tsimikas et al., 2020). Equally promising results have been observed with the siRNA olpasiran and second-generation compounds. This article argues that recognizing Lp as a legitimate therapeutic target requires a revision of screening guidelines and preparation of clinical practice for the imminent incorporation of these therapies. It is concluded that gene silencing of Lp constitutes the most promising frontier of personalized preventive cardiology, and that the Lp HORIZON result marks the inflection point between historical neglect and causal intervention.

Authors

Publication Details

Journal
Revista fisio&terapia.
Published
2026-11-18
DOI
https://doi.org/10.69849/0k3p4a14
Primary Topic
Lipoproteins and Cardiovascular Health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Lipoproteína: o fator de risco cardiovascular genético negligenciado e as terapias de silenciamento gênico após o resultado do LP Horizon

Edson da Silva Ribeiro, Josué Moura Telles, Luís Eduardo da Silva Malta, Ludymila Cristal Miranda Ferreira
2 links
Revista fisio&terapia.
Lipoproteins and Cardiovascular Health
article

Lipoproteína: o fator de risco cardiovascular genético negligenciado e as terapias de silenciamento gênico após o resultado do LP Horizon

Edson da Silva Ribeiro, Josué Moura Telles, Luís Eduardo da Silva Malta, Ludymila Cristal Miranda Ferreira
article en

Abstract

Lipoprotein is a lipid particle of predominantly genetic origin whose elevated plasma levels are causally and independently associated with the risk of atherosclerotic cardiovascular disease and calcific aortic stenosis. Despite its significant population prevalence an estimated 20% of individuals carry risk-associated concentrations Lp measurement remains absent from most routine cardiovascular screening strategies, constituting a neglected risk factor in clinical practice. This article reviews the pathophysiology of Lp, its genetic determination by the LPA locus, the epidemiological and genetic evidence supporting a causal relationship with cardiovascular outcomes, and the emerging therapeutic landscape. Traditionally, available pharmacological interventions such as statins exert minimal or no effect on Lp. However, the advent of gene-silencing therapies based on antisense oligonucleotides and small interfering RNA represents a paradigm shift. The phase 2 Lp(a)HORIZON trial demonstrated that olpasiran, an ASO targeting apo mRNA, produced dose dependent reductions of up to 80% in Lp levels in patients with established cardiovascular disease, with an acceptable safety profile (Tsimikas et al., 2020). Equally promising results have been observed with the siRNA olpasiran and second-generation compounds. This article argues that recognizing Lp as a legitimate therapeutic target requires a revision of screening guidelines and preparation of clinical practice for the imminent incorporation of these therapies. It is concluded that gene silencing of Lp constitutes the most promising frontier of personalized preventive cardiology, and that the Lp HORIZON result marks the inflection point between historical neglect and causal intervention.

Revista fisio&terapia.Vol. 30(164)
Good health and well-being
Lipoproteins and Cardiovascular Health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon